Biotechs count the cost of Trump’s tariffs
Post Liberation Day, a number of life science companies have clarified the likely impact of Trump’s tariffs – and the news is largely positive.
Stockhead
REE supply uncertainty brought into spotlight
China’s restrictions on exports of medium and heavy rare earths will disrupt global supply chains, opening the door for Western miners.
Did this biotech hit unicorn status without hurdles? Of Coris not
The Coris FDA assent isn’t the first rodeo for Nanosonics, given its inaugural Trophon device has been commercialised since 2009. What next for the billion-dollar biotech?
Long Shortz: Orthocell
Orthocell has finally been given FDA approval for its nerve repair product Remplir, a major milestone for the company.
More Stories
A medical comms outfit at the pointy end of a tough market
Medadvisor doesn’t make vaccines, but it helps vaccine makers to promote the importance of immunisation (and boost sales of their drug). These days, that’s a tougher sell than ever.
ASX edges ahead as Trump’s tariffs news awaits
The ASX got over the line for a win, despite curbed afternoon enthusiasm. Traders, investors and pretty much anyone who cares about the economic state of the world await the next act in The Trump Tariffs Circus.
Trump tariffs hit hard but CSL, TWE stay strong
Trump’s tariffs have hit global exports, with China copping it the hardest and Australia facing a 10pc levy. Meanwhile, safe haven gold hits record highs. (Again.)
Liberation Day brings not so tariff-ic surprises
While Australia could have fared worse, Donald Trump’s raft of punitive tariffs have rattled investors.
Cavalier hits record after robust gold PFS
Cavalier Resources is basking in the warmth of a robust revised PFS for the Crawford Gold Project in WA, hitting a record 24c.
Hundreds of mine workings found by NSW explorer
Resolution Minerals has found 791 historical workings relating to gold and antimony prospects at its Drake East project in NSW.
ASX sinks, supermarkets rise in global chaos
The ASX tanked by more than 2.4pc on Friday as Trump’s tariffs stirred up global chaos. Breville and Ansell scrambled to adjust.
Big names place spotlight on West African goldie
West African gold explorers have proven some of the ASX’s best stories. A new one has just popped up on Garimpeiro’s radar.
BGL reveals gold crunch
Bellevue Gold remains suspended, but has revealed its expected March quarter gold performance before a potential guidance downgrade.
ASX health stocks fall but Orthocell nabs FDA approval
In the midst of tariff mayhem this week, finally some good news has landed, with Orthocell gaining a big FDA approval win in the US.
Original URL: https://www.thechronicle.com.au/business/stockhead/page/12